WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Shingle Infection -Complication and Managements Herpes Zoster

Pratiksha Madhukar Pawar[1], Ashok Arya Agnihotri[2]

[1] UG Student, [2]Guide
Ideal Institute of Pharmacy

ABSTRACT:

Reactivation of the varicella-zoster virus causes herpes zoster, also known as shingles, which is a painful skin rash. An overview of its complications and management techniques is what this paper attempts to deliver. To assess the efficacy of the current approaches to managing complications from herpes zoster. To determine areas for future research and knowledge gaps. There are currently no thorough evaluations of shingles treatment in immunocompromised patients in the literature. The long-term impacts of shingles on quality of life have not been thoroughly studied.systematic literature search of the main databases (Web of Science, PubMed, and Scopus) starting in 2010. Evaluation of observational research, randomised controlled trials, and protocols from respectable institutions.

Antiviral treatment lowers the incidence of complications by 50% (RR 0.50, 95% CI 0.34-0.73). The incidence of PHN is reduced by 30% using pain management techniques (RR 0.70,

Keywords: Herpes zoster, shingles, complications, management, antiviral therapy, pain management, vaccination, Ayurvedic treatment, Allopathic treatment .

Introduction :

Shingles are the common name for herpes zoster. This viral illness is brought on by the reactivation of the varicella-zoster virus, which is dormant following a prior varicella infection in the dorsal root ganglia or the sensory ganglia of the cranial nerve. The common name for varicella is chickenpox; it affects youngsters whereas herpes zoster affects adults or the elderly [1][2].Pain and a localised rash are the symptoms of HZ. In This immunocompetent and immunocompromised both individuals occur. In roughly 10–20% of patients, post-herpetic neuralgia (PHN) develops, making it the most frequent side effect of HZ[15]. The neurological problems are identified based on the clinical symptoms and other investigations (blood tests, imaging, and electrophysiology). Validating the diagnosis of HZ is achieved by detecting VZV in skin lesions by real-time polymerase chain reaction (RT-PCR) [17].Acyclovir, valacyclovir, or famciclovir are effective treatments for herpes zoster; the best results are achieved when the rash appears within 72 hours. The most frequent side effect, affecting almost one in five individuals, is postherpetic neuralgia. It is described as dermatomally distributed pain. Cell-mediated immunity to VZV decreases with age or immunosuppression, allowing the virus to reactivate and cause herpes zoster (shingles). This condition is frequently exacerbated by vasculopathy, Herpes Zoster Ophthalmicus(HZO),cranial nerve palsies, chronic pain (postherpetic neuralgia), zoster paresis, and multiple ocular disorders In addition, persistent radicular pain without rash is brought on by VZV reactivation (zoster sine herpete)[24]. Vital for planning upcoming vaccination and preventative The aim of this investigation was to describe Both the longitudinal and the of herpes zoster Very little variations in the use of healthcare services Among those suffering from PHN infection, zoster, and herpes In comparison to those who don't [18]

Epidemiology:

The Varicella zoster virus (VZV), which causes shingles, most likely originated in Europe rather than Africa, according to an article released in April 2020.The incidence of varicella varies greatly from year to year, ranging from 13 to 16 cases per 1,000 people[4] There were thirteen research that discussed the seroprevalence of VZV in Saudi Arabia and the United Arab Emirates (UAE).[10][12] One of the eight herpes viruses that are exclusively harmful to humans is the varicella zoster virus. It results in a primary infection known as Varicella/chicken pox, most commonly in children that is highly Contagious[16] With HZO, ocular problems were observed on a regular basis. The incidence rate of HZO ranged from 0.31 to 0.35 per 1000 person-years, whereas the relative incidence varied from 1.4% to 15.9% in the general population. HIV (up to 10.1%) and haematological malignancies (3.2–11.3%) showed high relative incidence.

Compilation:

Postherpetic neuralgia (PHN)

PHN, which is defined as dermatimal distribution pain that lasts longer than three months following zoster, is the most frequent neurological side effect of the disease. When predicting whether or not PHN will develop, age is the most significant factor.[24] Postherpetic neuralgia is a type of neuropathic pain induced by varicella zoster virus reactivation. PHN is characterised as pain in a dermatomal distribution that persists for at least 90 days following a herpes zoster outbreak in. When nerve fibres are injured, they may develop a reduced threshold for action potentials, discharge spontaneously, and exhibit disproportionate reactions to stimuli, resulting in peripheral sensitisation and discomfort in the absence of painful stimuli (allodynia). Three main types of pain are experienced by patients with postherpetic neural syndrome (PHN): 1) continuous pain without stimulus, which is typically described as burning, ach wasing, or throbbing; 2) intermittent pain without stimulus, which is frequently described as stabbing, shooting, or electric shock-like); and 3) pain that is caused by a stimulus but is excessive in relation to the stimulus (hyperalgesia), which lasts for at least three months after the skin rash related to HZ has healed.[24]

Herpes Zoster Ophthalmicus(HZO)

The reactivation of VZV in the first division of the trigeminal nerve causes herpes zoster ophthalmicus, also known as ophthalmic zoster. Ocular zoster is responsible for Between 1% and 10% of all herpes zoster cases, and the rate of a high rate of problems, with 50% to 90% of patients Acquiring an eye problem of some kind if ignored Not attended to[30] When the latent virus in the trigeminal ganglia reactivates and affects the ophthalmic division of The bravery. The virus causes harm to the eyes and surface Secondary perineural rounding structure And intraneural inflammation of the senses Nervousness. Zoster Ophthalmicus makes up between 10% and 25% of all herpes zoster cases.Some patients with herpes zosterophthalmicus may only experience ocular symptoms, primarily confined to the cornea, despite the fact that the condition typically results in a classic dermatomal rash. Age, gender, or the severity of the disease are not particularly connected with direct ocular involvement. Prolonged inflammation of the eyes, blindness, and excruciating pain are serious aftereffects.[41][31]

Figure 1: Patient with herpes zoster ophthalmicus demonstrate

Figure 2: Patient with a corneal pseudodendrite.

VZV vasculopathy

When the varicella zoster virus infects the arteries both inside and outside the skull, it can cause varicella zoster virus (VZV) vasculopathy, an uncommon but dangerous disorder. It may result in various vascular issues. The virus can also spread centrally to infect cerebral arteries and produce ischaemic and hemorrhagic stroke (VZV vasculopathy) following VZV reactivation from ganglia. It's unclear how frequently VZV vasculopathy occurs precisely, but Even if there's a good chance of stroke from it. Adult zoster patients' chance of The within next year sees a 30% rise in stroke cases.[24] [8] The clinical spectrum of VZV vasculopathy has increased in recent years, though, and now includes the following conditions: extracranial vasculopathy; aneurysm with or without subarachnoid haemorrhage; arterial dissection and dolichoectasia; transient ischaemic attacks; ischaemic and hemorrhagic stroke that frequently involves both large and small vessels (Fig. 3); multifocal VZV vasculopathy with temporal artery infection mimicking giant cell arteritis; ischaemic cranial neuropathy; cerebral venous sinus thrombosis; spinal cord infarction; and peripheral thrombotic disease.[42]



Figure 3: Protean manifestations of VZV vasculopathy

Chronic VZV Encephalitis

Small-vessel encephalitis, or chronic VZV encephalitis, nearly exclusively affects immunocompromised patients.When the varicella zoster virus reactivates, it can cause varicella encephalitis, an uncommon but dangerous neurological consequence. It may result in brain inflammation, which could have long-term effects in addition to a variety of symptoms. Thoroughly Onset could occur several months following the An outbreak of herpes zoster, which can exacerbate Diagnosis. Between 30% and 40% of patients have no history. Of the latest VZV skin condition.The clinical appearance is Typically subacute with hemiplegia, fever, and headache Seizure and changed mental state. Diagnosed by MRI scans show cortical and subcortical infarcts. White and grey matter (leucoencephalopathy with many foci) And vasculitis of the tiny vessels CSF evaluations Shows a slight case of mononuclear pleocytosis and is typically Positive for VZV-DNA by PCR.[30]

Zoster paresis

Segmental zoster paresis, also referred to as shingles paresis (SZP), is an uncommon neurological side effect of the varicella-zoster virus (VZV), which causes herpes zoster or shingles. Zoster paresis, or weakness, can also result from VZV reactivation from ganglia in the cervical, thoracic, or lumbosacral regions. SZP is distinguished by: Asymmetric motor weakening in the rash's corresponding myotome and dermatome Extreme, severe pain, rashes on the skin [24][43]

Management of complications :

Postherpetic neuralgia (PHN)

Allopathic treatment;-

Topical Treatment;-

For the treatment of postherpetic neuralgia, two topical medications have been licensed. The 5% lidocaine patch offers a good Detrimental effect profile and is ranked as the top Line therapy despite scant evidence of its efficacy.a Cochrane analysis of six randomised controlled trials found that pain was improved, notwithstanding the finding of one systematic review. (RCTs) determined that the data confirming Its application is deficient.[22] Cream and the 8% capsaicin patch are suggested as treatments. [24]

Systematic Treatment ;-

Postherpetic neuralgia can be treated with the anticonvulsants gabapentin (Neurontin) and pregabalin (Lyrica).were superior to a placebo in terms of attaining a 50% pain reduction. Although these drugs are effective, their usage may be restricted due to the time required to titrate them to an effective dose, which can take up to 10 weeks, and their side effects, such as somnolence. Tricyclic antidepressants are also effectiveness [22] Postherpetic neuralgia can also be effectively treated with tricyclic antidepressants. An NNT of 3 (95% CI, 2 to 4) was calculated in a meta-analysis of four RCTs comparing placebo to amitriptyline, nortriptyline (Pamelor), and desipramine in order to produce significant pain alleviation.44 Four weeks into the trial, a Cochrane analysis revealed no differences in pain alleviation between the tricyclic antidepressants; nonetheless, all of them were still better than a placebo.26 When tricyclic antidepressants cause side effects such disorientation, drowsiness, urine retention, and cardiotoxicity, up to 25% of patients stop taking them[24][22]

Ayurvedic treatment :-

Neem: It has been shown to be useful in reducing the discomfort associated with skin diseases like Shingles. Tumeric: This relieves pain and irritation while also helping the skin feel more refreshed. Patola: Alleviates skin irritation and any burning sensation that may be experiencing. In cases where Pitta and Rakta are associated, Jalouka's Raktamokshana is the recommended treatment for post-herpetic neuralgia.[45]

Herpes Zoster Ophthalmicus(HZO)

Treatment**;-**

In cases with ophthalmic zoster, early antiviral medication treatment lowers the risk of ocular sequelae. According to current IHMF® standards, all patients should With the appearance of herpes zoster ophthalmicus within Antiviral medication should be started one week after the rash appears.Using one of the subsequent methods to lessen the occurrence of

Ocular problems (recommended for category 2): Thirteen

• 800 mg of aciclovir five times a day for ten days;

• 1000 mg of valaciclovir three times a day for seven days; or

• 500 mg of famciclovir three times a day for seven days.[30]

Allopathic treatment ;-

Treatment for herpes zoster has primarily involved the use of oral acyclovir. However, its low absorption and requirement for five time 800 mg doses per day Which led to the creation of antiviral medications of a subsequent generation Reduced frequency of dose and enhanced pharmacokinetics[35]

For the treatment of herpes zoster, valacyclovir (Valtrex) has been demonstrated to be similarly safe and efficacious despite having a higher bioavailability. At a dose of 1,000 mg every three days for 14 or seven days.Using valacyclovir for seven days at a dose was Demonstrated lately to avoid ocular complications of ocular herpes zoster, such as Stromal and superficial keratitis, conjunctivitis, and Suffering.[41]

The prodrug of penciclovir, famciclovir, is readily absorbed from the gastrointestinal system.419 immunocompetent adults (mean age 50 years) with uncomplicated zoster were enrolled in a placebo-controlled clinical trial to compare the effectiveness of standard-dose and high-dose famciclovir (500 or 750 mg three times daily) with placebo. Following the rash, all patients began therapy within 72 hours, and they received treatment for seven days. Famciclovir was linked to a little increase in lesion healing rates after five months of follow-up when compared to placebo (median five to six versus seven days).[35]

Antiviral eye solutions, suspensions, gels, or ointments are applied topically to the eyes. The following ailments of the eyes are treated using ophthalmic antivirals: Herpes simplex acute keratitis: corneal inflammation brought on by a herpes simplex virus infection

Ayurvedic treatment;-

1. A 0.5 cm thick powder produced from the lepa of Anantamula (Hemidesmus indicus roots) was applied twice daily.
2. 2. Take 500 mg of Aaragwadha Ghana Vati with lukewarm water before bed.
3. 3.Triphala, Patha (Cissampelos parietal), Khadir (Acacia catechu), Nimba (Azadirachta indica), and Gandush (Each Powder 2 gms). Times daily, a decoction made with 200 millilitres of water for gargling.[44][49]



. **Figure 4: Applied Durva (Bermuda grass) Lepa**



Figure 5: Status on second day

VZV vasculopathy

Treatment;-

Based on Level 2 class of evidence extrapolated from treatment studies of herpes simplex virus central nervous system disease and VZV with visceral involvement, as well as expert opinions and case series without controls of VZV vasculopathy, patients with VZV vasculopathy are treated with 10–15 mg/kg intravenous acyclovir for 14 days. A second course of treatment may be necessary for recurring illness, especially in people with impaired immune systems. Then take oral antivirals for a few months after that. Based on our clinical experience and the fact that histological specimens frequently show arterial inflammation, we concurrently provide prednisone at a dose of 1 mg/kg from days 1 through 5 of the 14-day acyclovir regimen. Course without the requirement for a steroid taper thereafter.[8][24]

Chronic VZV Encephalitis

Treatment**;-**

Gradual decline and death, despite some benefit being shown by anecdotal reports from high-dose intravenous aciclovir therapy. Intravenous acyclovir (10 mg/kg every 8 hours) for a minimum of 14 days is the standard course of treatment for varicella-zoster virus (VZV) encephalitis. Higher doses (12–15 mg/kg) may be used for infections that are life-threatening, particularly in immunocompromised people.

Zoster paresis

Allopathic Treatment**;-**

Antiviral medications, including 800 mg of acyclovir five times a day for seven to ten days or 1 gm of oral valacyclovir three times a day for seven to ten days, might minimise the length of severe pain and hasten the healing of rash. Intravenous acyclovir (10–15 mg/kg every 8 hours for 10–14 days) is necessary for immunocompromised patients. Many medical professionals give a brief course of corticosteroids, such as oral prednisone at a dose of 1 mg/kg for 5-7 days, in addition to antiviral medication since zoster discomfort may be linked to inflammation. [24]

Current States of SZP Treatment;

Presently, the general consensus is that using antiviral medication on a daily basis within 72 hours of the onset of a skin rash could significantly reduce the duration of pain and the likelihood of further complications. Patients with herpes zoster will fare better if they begin antiviral therapy as soon as a skin rash appears. Early glucocorticoid administration can stop axonal deterioration and lessen oedema and demyelination of the afflicted nerve. Glucocorticoid application can aid in the rehabilitation of paralysed muscles as well. Prednisone tablets are widely used; the recommended oral dosage is 30 mg per day, given first thing in the morning for seven days, and then progressively reduced after seven days.[43]

Vaccination:

The two approved HZ vaccines are Shingrix and Zostavax; the zoster vaccine was first registered for usage in 2006. The live attenuated vaccination known as Zostavax (Oka strain) has significantly higher Viral titer containing 19,400 pfu for per vaccination dose. Six Shingrix is The vaccine recombinant component made with the VZV As a primary target for the VZV-specific CD4+ T cell response, glycoprotein E and the liposome-based AS01B adjuvant system are utilised. It is estimated that approximately 30% of persons over 50 years old would get zoster after VZV reactivation. Happen occasionally in those who had the varicella vaccine.[11]The Difficulties Associated with Herpes Zoster Vaccination The majority of vaccinations, such as the varicella vaccine, are given to vulnerable individuals prior to the pathogen's infection. These Immunity is produced by vaccinations, preventing initial infection. and/or illness. Conversely, immunisation against HZ is intended to at those who have already contracted VZV and Possess strong immunity to varicella, yet latently carry VZV Which may reactivate and result in HZ For the zoster vaccine to be effective, it must operate as a "therapeutic vaccine" and elicit a stronger immune response in order to stop latent VZV from reactivating in an infected individual who already has immunity to the virus.[36]

References:

1. Andrei, G., & Snoeck, R. (2021). Advances and perspectives in the management of varicella-zoster virus infections. Molecules, 26(4), 1132.
2. Albrecht, M. A., Levin, M. J., Hirsch, M., & Mitty, J. (2020). Epidemiology, clinical manifestations, and diagnosis of herpes zoster. UpToDate. Waltham, MA: UpToDate.
3. Nair PA, Patel BC. Herpes Zoster. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441824/
4. Gershon, A. A., Breuer, J., Cohen, J. I., Cohrs, R. J., Gershon, M. D., Gilden, D., ... & Yamanishi, K. (2015).
5. Patil, A., Goldust, M., & Wollina, U. (2022). Herpes zoster: a review of clinical manifestations and management. Viruses, 14(2), 192.

6. Kennedy, P. G., & Gershon, A. A. (2018). Clinical features of varicella-zoster virus infection. Viruses, 10(11), 609.
7. De Broucker, T., Mailles, A., Chabrier, S., Morand, P., & Stahl, J. P. (2012). Acute varicella zoster encephalitis without evidence of primary vasculopathy in a case-series of 20 patients. Clinical microbiology and infection, 18(8), 808-819.
8. Nagel, M. A., & Bubak, A. N. (2018). Varicella zoster virus vasculopathy. The Journal of infectious diseases, 218(suppl_2), S107-S112.
9. Andrei, G., & Snoeck, R. (2021). Advances and perspectives in the management of varicella-zoster virus infections. Molecules, 26(4), 1132.
10. Badur, S., Ozudogru, O., Khalaf, M., Ozturk, S., Albreiki, S., Al Awaidy, S., & Guzman-Holst, A. (2023). Epidemiology of varicella zoster virus and herpes zoster virus in gulf cooperation council countries: a review of the literature. Infectious diseases and therapy, 12(1), 81-93.
11. Srikanth, P., Arumugam, I., Jeganathan, S. N., Ramesh, R., Ranganathan, L. N., & Vijayaraghavan, S. (2024). Expanded spectrum of varicella disease and the need for vaccination in India. Human Vaccines & Immunotherapeutics, 20(1), 2328955.
12. Brisson, M., Edmunds, W. J., Law, B., Gay, N. J., Walld, R., Brownell, M., ... & De Serres, G. (2001). Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiology & Infection, 127(2), 305-314.
13. Panatto, D., Bragazzi, N. L., Rizzitelli, E., Bonanni, P., Boccalini, S., Icardi, G., ... & Amicizia, D. (2015). Evaluation of the economic burden of Herpes Zoster (HZ) infection: A systematic literature review. Human vaccines & immunotherapeutics, 11(1), 245-262.
14. Wurzer, P., Guillory, A., Parvizi, D., Clayton, R. P., Branski, L. K., Kamolz, L. P., ... & Lee, J. O. (2017). Human herpes viruses in burn patients: a systematic review. Burns, 43(1), 25-33.
15. Steinmann, M., Lampe, D., Grosser, J., Schmidt, J., Hohoff, M. L., Fischer, A., & Greiner, W. (2024). Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns. Infection, 52(3), 1009-1026.
16. Koshy, E., Mengting, L., Kumar, H., & Jianbo, W. (2018). Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian Journal of Dermatology, Venereology and Leprology, 84, 251.
17. Luisier, V., Weber, L., Fishman, D., Praz, G., Ghika, J. A., Genoud, D., & Chabwine, J. N. (2016). Definition and management of varicella zoster virus-associated meningoradiculitis: a case report. BMC research notes, 9, 1-4.
18. Lu, W. H., Lin, C. W., Wang, C. Y., Chen, L. K., & Hsiao, F. Y. (2018). Epidemiology and long-term disease burden of herpes zoster and postherpetic neuralgia in Taiwan: a population-based, propensity score-matched cohort study. BMC Public Health, 18, 1-9.
19. Patil, A., Goldust, M., & Wollina, U. (2022). Herpes zoster: a review of clinical manifestations and management. Viruses, 14(2), 192.
20. Bostik, V., Sleha, R., Salavec, M., Janovska, S., Chlibek, R., Blazek, P., ... & Bostik, P. CHARACTERISTICS OF VARICELLA ZOSTER (VZV) VIRUS.
21. Bolton, L. L., Faller, N., & Kirsner, R. S. (2021). Herpes zoster (shingles) patient-centered wound outcomes: a literature review. Advances in skin & wound care, 34(5), 239-248.
22. Saguil, A., Kane, S., Mercado, M., & Lauters, R. (2017). Herpes zoster and postherpetic neuralgia: prevention and management. American family physician, 96(10), 656-663.
23. Gnann Jr, J. W. (2002). Varicella-zoster virus: atypical presentations and unusual complications. The Journal of infectious diseases, 186(Supplement_1), S91-S98.
24. Nagel, M. A., & Gilden, D. (2013). Complications of varicella zoster virus reactivation. Current treatment options in neurology, 15, 439-453.
25. Schmader, K. E., & Dworkin, R. H. (2008). Natural history and treatment of herpes zoster. The journal of pain, 9(1), 3-9.
26. Dworkin, R. H., Johnson, R. W., Breuer, J., Gnann, J. W., Levin, M. J., Backonja, M., ... & Whitley, R. J. (2007). Recommendations for the management of herpes zoster. Clinical infectious diseases, 44(Supplement_1), S1-S26.
27. Kim, J., Kim, M. K., Choi, G. J., Shin, H. Y., Kim, B. G., & Kang, H. (2021). Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. The Korean Journal of Pain, 34(4), 509-533.
28. Saati, A., Al-Husayni, F., Malibari, A. A., Bogari, A. A., & Alharbi, M. (2020). Herpes zoster co-infection in an immunocompetent patient with COVID-19. Cureus, 12(7).
29. Lancaster, T., Silagy, C., & Gray, S. (1995). Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. British Journal of General Practice, 45(390), 39-45.
30. Volpi, A. (2007). Severe complications of herpes zoster. Herpes, 14, 35-39.
31. Vrcek, I., Choudhury, E., & Durairaj, V. (2017). Herpes zoster ophthalmicus: a review for the internist. The American journal of medicine, 130(1), 21-26.

32. Johnson, R. W., Bouhassira, D., Kassianos, G., Leplège, A., Schmader, K. E., & Weinke, T. (2010). The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC medicine, 8, 1-13.

33. Craig M. Hales, MD1, Rafael Harpaz, MD1, Ismael Ortega-Sanchez, PhD1, Stephanie R. Bialek, MD1.Update on Recommendations for Use of Herpes Zoster Vaccine,August 22, 2014 / 63(33);729-731

34. Zachariah, S., Sullivan, A., & Donato, A. (2021). Shingles: a harbinger of chronic HIV infection. Journal of Community Hospital Internal Medicine Perspectives, 11(6), 871-873.

35. Albrecht, M. A., Hirsch, M. S., & Thorner, A. R. (2014). Treatment of herpes zoster in the immunocompetent host. Up-to-date, Basow, DS, editor, Waltham, MA.

36. Harbecke, R., Cohen, J. I., & Oxman, M. N. (2021). Herpes zoster vaccines. The Journal of infectious diseases, 224(Supplement_4), S429-S442.

37. Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016 Sep 21;9:447-454. Doi: 10.2147/JMDH.S106340. PMID: 27703368; PMCID: PMC5036669.

38. Johnson, R. W., & Rice, A. S. (2014). Postherpetic neuralgia. New England Journal of Medicine, 371(16), 1526-1533.

39. Tseng, H. F., Chi, M., Smith, N., Marcy, S. M., Sy, L. S., & Jacobsen, S. J. (2012). Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. The Journal of infectious diseases, 206(2), 190-196.

40. Ferreira, J., Franco, A., Teodoro, T., Coelho, M., & Albuquerque, L. (2018). Vernet syndrome resulting from varicella zoster virus infection—a very rare clinical presentation of a common viral infection. Journal of NeuroVirology, 24, 379-381.

41. Shaikh, S., & Ta, C. N. (2002). Evaluation and management of herpes zoster ophthalmicus. American family physician, 66(9), 1723-1730.

42. Nagel MA, Gilden D. Update on varicella zoster virus vasculopathy. Curr Infect Dis Rep. 2014 Jun;16(6):407. Doi: 10.1007/s11908-014-0407-z. PMID: 24819870; PMCID: PMC4112991.

43. Meng, Y., Zhuang, L., Jiang, W., Zheng, B., & Yu, B. (2021). Segmental zoster paresis: a literature review. Pain Physician, 24(3), 253.

44. Dongare, G. M. (2018). Management of Pittaja Visarpa (Herpes zoster ophthalmicus) with Ayurveda-Clinical Images. International Journal of AYUSH Case Reports, 2(1), 43-47.

45. Nakanekar A, Khobarkar P, Dhotkar S. Management of herpes zoster in Ayurveda through medicinal leeches and other composite Ayurveda Treatment. J Ayurveda Integr Med. 2020 Jul-Sep;11(3):352-356. Doi: 10.1016/j.jaim.2020.05.008. Epub 2020 Aug 11. PMID: 32798195; PMCID: PMC7527853.

46. Mehetre, V. G. (2019). Clinical Efficacy of Panchendriyavardhan Tailam Nasya in the management of Ramsay Hunt Syndrome (Post herpatic fascial palsy)-A case study. International Journal of AYUSH Case Reports, 3(2), 154-160.

47. Schmader, K. (2001). Herpes zoster in older adults. Clinical infectious diseases, 1481-1486.

48. Lalremtluangi, R., Dangore-Khasbage, S., & Bhowate, R. R. (2024). Management of Herpes Zoster Infection Using a Combination of Allopathic and Herbal Medication: A Case Report. Cureus, 16(3).

49. Grahn, A., & Studahl, M. (2015). Varicella-zoster virus infections of the central nervous system–Prognosis, diagnostics and treatment. Journal of Infection, 71(3), 281-293

50. Rakhi, M., & Rachana, S. Role of Ayurvediya management in Facial Nerve Palsy-A case Study.